
Opinion|Videos|May 29, 2024
Diabetes, GLP-1, and Lipid Reduction
Michael Blaha, MD, highlights the potential of GLP-1 agonists in lowering LDL cholesterol, triglycerides, and body weight in patients with diabetes, presenting them as an additional option for reducing cardiovascular risk in this patient population.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
FDA Approves Roflumilast 0.3% Cream for PsO in Children 2-5 Years
2
FDA Issues CRL for Oxylanthanum Carbonate in Hyperphosphatemia for CKD Patients on Dialysis
3
Functional Cures for T1D: Insulin Independence Through Islet Transplantation
4
Hypercortisolism as a Driver of Hypertension and Cardiovascular Risk
5

























































































